Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Wave Life Sciences Announced The Initiation Of Dosing In The Phase 2 Forward-53 Clinical Trial, Which Is Evaluating WVE-N531 As A Treatment For Boys With Duchenne Muscular Dystrophy Who Are Amenable To Exon 53 Skipping

Author: Benzinga Newsdesk | December 15, 2023 09:31am

FORWARD-53 is fully enrolled with potentially registrational dystrophin expression data expected in 2024

Previous clinical proof-of-concept data demonstrated highest level of exon skipping ever observed in the clinic and that WVE-N531 was present in myogenic stem cells, which are important for potential muscle regeneration

Posted In: WVE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist